Nucléosides

TFA-aa-dC is a novel anti-cancer drug that has been shown to have both antiviral and anticancer activities. It is a modified phosphoramidite of 2'-deoxyadenosine 5'-triphosphate with a 3'-amino group (TFA-aa-dC) and an acetyl group at the 2' position. TFA-aa-dC blocks viral replication by inhibiting the activity of viral DNA polymerase, which is required for DNA synthesis. The compound also inhibits cell growth by blocking RNA synthesis and protein production, leading to cell death. TFA-aa-dC has shown efficacy in preclinical studies against cervical cancer and leukemia cells.

2'-Deoxycytidine-5'-carboxylic acid (2'-DC) is a modified nucleoside that has been used as an anticancer, antiviral, and synthetic agent. 2'-DC inhibits the synthesis of DNA by binding to the enzyme DNA polymerase. It also inhibits viral replication by inhibiting the activity of reverse transcriptase and can be used as a potential anti-HIV drug. In addition, 2'-DC has been shown to have cytotoxic effects against cancer cells in vitro. This compound is synthesized from cytidine 5-monophosphate and phosphoramidite reagents in high purity and quantity. The CAS number for this compound is 4603-72-9.

N4-Acetyl-5'-O-DMT-cytidine 3'-succinyl CPG 1000 Å (RNA) is a novel, high quality, high purity, synthetic nucleoside analogue. It has antiviral and anticancer properties.

6-Methylthioinosine-5’-triphosphate sodium salt - 10 mM aqueous solution is a synthetic, modified ribonucleoside that is an activator of the antiviral response. It has been shown to inhibit the replication of both DNA and RNA viruses in vitro. 6-Methylthioinosine-5’-triphosphate sodium salt - 10 mM aqueous solution is also used as a precursor in the synthesis of phosphoramidites. The CAS number for this product is 51464-82-5.

Emtricitabine-d2,15N is a labelled version of emtricitabine. It is a nucleoside reverse transcriptase inhibitor that inhibits the HIV-1 virus by blocking the activity of the enzyme needed to convert RNA into DNA. This drug also offers long-term efficacy and can be used in combination with other antiretroviral agents including tenofovir alafenamide hemifumarate (TAF) and tenofovir disoproxil fumarate (TDF). The addition of TAF or TDF to emtricitabine-d2,15N provides an active antiretroviral therapy for HIV/AIDS patients. Emtricitabine-d2,15N has shown to reduce viral load significantly in people taking it as part of their treatment regimen.

1-(2-C-Methyl-b-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide is a modified nucleoside that is used as an antiviral and anticancer agent. It is a diphosphate derivative of 1-(2'-deoxyribofuranosyl)-1H-1,2,4-triazole. The compound has been shown to have antiviral activity against herpes simplex virus (HSV) type I and HSV type II in vitro. It also inhibits the growth of human tumor cells in culture by interfering with DNA synthesis. The compound has been reported to be active against leukemia cells in vivo but not against normal cells. It has a high level of toxicity at high doses.

2'-Deoxyguanosine-5'-O-(1-thiotriphosphate) lithium salt is a nucleotide analog that has been shown to inhibit the synthesis of fatty acids and proteins, as well as cause depression in mice. It also has antiviral activity against the type strain of HIV-1 (HXB2). The drug inhibits protein synthesis by preventing the incorporation of amino acids into a growing polypeptide chain. This inhibition can be reversed by adding vitamin D3 or fatty acids. 2'-Deoxyguanosine-5'-O-(1-thiotriphosphate) lithium salt has been shown to have anti-cancer properties due to its ability to induce apoptosis, which is programmed cell death. This drug also has immune functions, such as an increase in natural killer cells and cytokines, as well as improving energy efficiency in the optical system.